- Investing.com
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Metrics to compare | PALI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPALIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.2x | −4.4x | −0.4x | |
PEG Ratio | −0.19 | −0.10 | 0.00 | |
Price/Book | 2.4x | 4.7x | 2.6x | |
Price / LTM Sales | - | 11.6x | 3.2x | |
Upside (Analyst Target) | 284.6% | 55.4% | 50.9% | |
Fair Value Upside | Unlock | −0.6% | 6.8% | Unlock |